The content on this site is intended for healthcare professionals only
Dr Jones speaks at EONS 10, considering the side effects of CDK inhibition, including a class-wide tendency towards neutropenia, and how they might be managed with dose interruption.
CDKs were also discussed at an ecancer symposium at ESMO 2016.
Supported by a grant from Pfizer Inc.
ASCO GU 2026: Updates in renal cancer
Breast cancer survivorship
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
